Sign in to view content

GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results

Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS

Video
Published 2022

Related

Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy
David S. Boyer, MD
Updates from the Field
2017
Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study
W. Lloyd Clark, MD, FASRS
Updates from the Field
2022
Charlson Comorbidity Index As a Predictive Tool in Patients With Exudative Age-Related Macular Degeneration in Delay of Care
Vivienne S. Hau, MD, PhD
Annual Meeting Talks
2024

Category: AMD-Non-Neovascular

See more